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A B ST R AC T 
 
 
We present a literature review which summarizes the data supporting 
one of the alternative perspectives on the effect of alcohol consumption 
on cognitive aging – the possible positive effect of low to moderate 
drinking. Some of the main theories about aging, the mechanisms of 
brain aging, and the pathogenesis of cognitive decline and dementia are 
briefly described. In this context, the putative mechanisms of the 
protective action of non-alcoholic components in alcoholic beverages or 
low doses of ethanol against oxidative stress, inflammation, 
mitochondrial dysfunction, brain insulin resistance, and production of 
amyloid-β peptides are presented. The review article does not favor the 
data selected and highlighted, but it aims at inspiring more interest and 
further research on the topic.   
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Aging is defined as an age-related progressive inability 
of the body's internal and genetic mechanisms to defend, 
maintain and repair themselves in order to continue to 
function effectively [1]. As a result, many harmful changes 
accumulate in the cells and tissues with age. The cell loss 
and dysfunction that occur during normal aging lead to 
impaired organ functioning and inter-organ 
communication in the physiological systems and the body 
as a whole. The declining biological functions decrease 
resistance and adaptability, while the risk of diseases and 
death increases [2,3]. 
 The outlined life perspective logically raises two 
existential questions: 1) whether the inevitable can be 
delayed and 2) how to live the allotted time. From a 
scientific point of view, these issues belong to the field of 
the so-called Anti-Aging Medicine [1]. Numerous studies 
have focused on different means of slowing down aging 
and prolonging life. There have been many attempts to find 
optimal diets and lifestyles that contribute to healthy 
longevity. Inevitably, when it comes to nutrition, the 
question of alcohol consumption arises [4]. This literature 
review focuses on the currently available data about the 
beneficial effects of moderate alcohol drinking as an 
important component of "successful" aging – cognitive 
integrity. Understanding the mechanisms of the potentially 
beneficial effects of moderate alcohol use implies 
knowledge of normal brain aging. 
Discussions 
The process of aging 
The research on age-related physiological changes and 
their causes reveals aging as an extremely complex and 
multifactorial process. There are over 300 theories about 
aging, which should not be considered as mutually 
exclusive, but rather complementary in an attempt to 
explain the signs of the normal aging process [5,6]. 
 According to the theory of free radicals, aging is the 
result of the accumulation of endogenous reactive oxygen 
species (ROS), and the associated oxidative stress [7]. The 
mitochondrial theory of aging focuses on ROS-induced 
mitochondrial DNA damage [8,9].  The well-known link 
between inflammation and oxidative stress relates the 
inflammatory hypothesis of aging to the free radical theory 
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of aging [10]. Overproduction or the uncontrolled release 
of reactive oxygen and nitrogen species and the reduced 
capacity of endogenous antioxidant mechanisms are the 
major causative factors of tissue inflammation. The 
dysfunction in the regulatory pathways, occurring with 
age, upsets the balance between anti- and proinflammatory 
agents in favor of the latter, and maintains chronic 
inflammation. The immune theory of aging suggests that a 
network of cellular and molecular mechanisms, including 
DNA repair systems, enzymatic and non-enzymatic 
antioxidant systems, the production of heat-shock proteins, 
etc. controls the aging process indirectly [11].  All these 
mechanisms limit the negative effects of various physical, 
chemical, biological, etc. stressors and increase life 
expectancy.  
In addition, the neuroendocrine-immune hypothesis 
draws attention to the interaction between the nervous, 
endocrine, and immune systems including different 
neurotransmitters, neuropeptides, and cytokines [8]. 
According to the waste accumulation theory, the inability 
to effectively remove the non-degradable by-products of 
metabolism with subsequent accumulation of metabolic 
wastes contributes to cell aging [6].  Examples of 
extracellular deposits are cholesterol-containing plaques in 
blood vessels, and protein polymers, such as β-amyloid, in 
the central nervous system (CNS) (amyloid plaques). In 
summary, the current theories on aging demonstrate that 
different processes contribute to aging; they interact and 
simultaneously work at different levels of functional 
organization [12]. 
Brain aging and cognitive functions 
As people advance in age, the efficiency of brain 
functions, in particular the cognitive ones, are negatively 
altered. By definition, cognitive functions encompass those 
mental processes through which knowledge is acquired and 
the understanding of the world occurs – perception, 
attention, memorization, reasoning, evaluation, problem-
solving, decision making, creativity, and speech [13,14]. 
Observations show that the age-related decline in cognitive 
functions in healthy people begins in the third decade of 
life and continues throughout life. [4]. 
 Aging is an irreversible process that depends on 
genetic and environmental factors and involves 
complicated metabolic and molecular mechanisms. The 
cardiometabolic mechanism reveals that the vascular 
pathology associated with obesity, type 2 diabetes, and the 
metabolic syndrome, contributes to cognitive decline and 
dementia in adults. However, the problems are not limited 
to reduced brain perfusion. An interesting aspect of the 
metabolic mechanisms is the defective insulin sensitivity 
and signaling in the brain [15-17].  Insulin regulates the 
energy metabolism of neurons, as well as their 
differentiation, growth, survival, synaptic plasticity, and 
neurotransmission. In the hippocampus, it contributes to 
the long-term potentiation, thus affecting learning and 
memory. Therefore, brain insulin resistance will disturb the 
above-mentioned processes. Recently, researchers have 
proposed the phrase "type 3 diabetes" for Alzheimer's 
disease, because of the shared molecular and cellular 
characteristics between insulin resistance and cognitive 
decline in the elderly [18]. 
Vitamin D is another pleiotropic regulator, which is 
involved in the neurodegenerative processes that occur 
with aging. Vitamin D deficiency, which is common in 
elderly people, is considered a risk factor for cognitive 
decline and dementia [19-21]. Vitamin D plays a 
neurotrophic and neuroprotective role by stimulating the 
synthesis of neurotrophic agents such as nerve growth 
factor and neurotrophins in astrocytes and 
oligodendrocytes [22,23]; it regulates calcium 
homeostasis in the brain [24,25], it modulates brain 
neurotransmitters, and displays anti-inflammatory 
activity by suppressing the pro-inflammatory cytokines in 
the brain [26,27]. Moreover, vitamin D has an antioxidant 
activity and inhibits the generation of ROS, lipid 
peroxidation, and the inactivation of some antioxidant 
enzymes [28]. 
 The free radical theory of aging postulates that free 
radical reactions contribute to aging. The brain is one of the 
most metabolically active organs, where a delicate balance 
is maintained between the mechanisms of production of 
free radicals and the mechanisms of brain defense [29]. The 
moderate production of ROS by mitochondria, described 
as a physiological level of oxidative stress, is known to up-
regulate the program of mitochondrial biogenesis and the 
antioxidant capacity of the brain, and thus works in favor 
of brain protection. However, the accumulated oxidative 
damage and the deterioration of the mitochondrial function 
in the aging brain causes changes in cellular architecture. 
Therefore, it is logical to assume that the uncontrolled 
production of free radicals is a major factor in the loss of 
neuronal homeostasis and the development of 
neurodegenerative diseases [30].  
 Neuroinflammatory processes also contribute to brain 
aging. Experimental data from animal models with 
Alzheimer's disease and Parkinson's disease indicate that 
systemic inflammation initiates an exacerbated immune 
response in the CNS through the local innate immune 
system, the microglial cells. Microglia become easily 
susceptible to secondary inflammatory stimulation, which 
can elicit an excessive inflammatory response [31]. The 
sustained activation of microglia changes their functions 
and induces the increased secretion of proinflammatory 
cytokines and neurotoxic factors that contribute to the 
systemic inflammation and the progression of 
neurodegenerative diseases [32, 33]. 
Alcohol consumption, cognitive aging, benefits? 
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 Sometimes, it is difficult to distinguish between the 
normal changes in the aging brain and the incipient 
neurodegenerative processes. Alterations in brain tissue 
can precede the occurrence of clinical signs and/or 
neuropathological lesions by years and can be detected in 
elderly individuals who do not show cognitive decline 
[34].  
Therefore, a lot of effort has been invested in 
elucidating the pathogenesis of degenerative brain 
diseases and identifying reliable biomarkers for the 
diagnosis of preclinical and prodromal stages of 
dementia. Studies over the past 30 years have shown that 
the pathogenesis of Alzheimer's disease involves a 
plethora of events related to the impaired production, 
degradation, and clearance of amyloid-β protein (Aβ). 
The initial events of this plethora include the 
overproduction of amyloid-β precursor protein (AβPP) 
caused by rare mutations in the AβPP, PSEN1 or PSEN2 
genes, malfunctioning of Aβ-degrading proteases, and 
impaired Aβ clearance from the brain due to inefficient 
transport mechanisms [6,35].   
 The imbalance between production and clearance 
leads to an accumulation of excessive amounts of Aβ, 
which are thought to initiate a sequence of pathological 
changes such as loss of synapses and neurons, impaired 
glucose uptake, oxidative damage, the impairment of brain 
energy metabolism, tau hyperphosphorylation, and the 
formation of neurofibrillary tangles, amyloid plaque 
deposition and, ultimately, neurodegeneration. This 
complex cascade of pathological events continues in the 
course of the development of Alzheimer's disease, and 
leads to the accumulation of structural and functional 
damage to the brain, causing the key symptoms of the 
disease [35]. In this context, in addition to the established 
diagnostic biomarkers of Alzheimer's disease – 
cerebrospinal fluid Aβ42, total tau (tTau) and 
phosphorylated tau181 (pTau181) [36], the possibilities of 
detecting soluble forms of the amyloid precursor protein 
(APP) in cerebrospinal fluid and blood are also evaluated 
[37].  
Brain-imaging techniques (PET, MRI) also present a 
high potential for the structural-topographic assessment of 
pathological changes [4]. Recently, views on the 
pathogenesis of Alzheimer's disease have become more 
complex with the established role of oxidative damage 
associated with an increased production of ROS, the loss 
of mitochondrial function, altered metal homeostasis, and 
decreased antioxidant protection, which may affect the 
production and accumulation of Aβ and 
hyperphosphorylated Tau protein. The latter can become 
components of a vicious circle that can exacerbate 
mitochondrial dysfunction and ROS production [38]. 
The prevention and delay of cognitive aging through 
nutritional (food and drink) strategies 
To find the "fountain of youth" has been the 
everlasting dream of humankind. Through hygiene, 
vaccines, antibiotics, insulin, and high-tech interventions, 
advanced medicine has led to increased life expectancy 
over the last century. This is currently a global trend. 
According to the data from the European Commission 
and Eurostat, by the year 2060, the elderly population 
(aged 65 and above) is expected to grow from 17.4% to 
almost 30% [4], while for the population over the age of 
80, the increase is expected to increase fivefold [39]. This 
inevitably raises the question of the quality of life of this 
growing share of the human population, which largely 
depends on full cognition. As part of the efforts of "anti-
aging" medicine, optimal means, interventions, and 
approaches for slowing down cognitive aging and the 
prevention of neurodegenerative diseases are sought [40]. 
However, it must be acknowledged that preventive 
methods have a limited capacity and that there are 
currently no means of stopping or reversing the aging 
process in humans. This gives rise to tendencies to 
develop complex strategies for maintaining cognitive 
health.  
Preclinical and clinical studies on healthy individuals 
or people in the early stages of cognitive decline have 
shown the potential of nutrition to exert a beneficial effect 
on cognitive functions [4,41]. It is well known, not only 
in the scientific community, that long-term adherence to 
the Mediterranean diet (rich in fruits, vegetables, nuts, 
olive oil, moderately saturated with fish and poorer in red 
meat) is associated with better cognition in adults and 
reduced risk of dementia or Alzheimer's disease 
[38,42,43]. Moderate drinking of mainly red wine is 
commonly reported as a component of the Mediterranean 
diet. Wine is not the only alcoholic beverage that is 
present on the table of different nations. This increases 
the scientific interest in the potential health benefits 
(including mental) of moderate alcohol consumption 
worldwide [44]. 
 The interest is not only global, but also ancient. The 
Sumerian cuneiform and Egyptian papyri, dating back to 
2200 BC, contain prescriptions for wine-based medicines 
[38,45]. In ancient Greece, Hippocrates (460-370 BC) 
considered wine to be part of a healthy diet and even 
prescribed it as a medicine for some diseases [45]. 
Speaking of ancient Greece, it is interesting to quote the 
poet Ebulus, who presents views on moderate wine 
consumption in one of his plays: "For moderation, three 
kiliks (three cups) are placed: one for health, the first to be 
emptied, the second for love and pleasure, and the third for 
sleep." [46]. Historical data about the suitability of wine for 
the treatment of dementia, in particular, can be found in the 
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first printed book on wine, written by the physician and 
theologian Arnaldus de Villa Nova in the 14th century [47]. 
 Тhe views and practices of ancient and medieval 
physicians do not seem unfounded, because studies and 
literature reviews from the late 20th and early 21st 
centuries provide evidence that moderate alcohol use in 
middle age and older age can be considered, albeit 
cautiously, protective against dementia in old age. An 
analysis of the results of the epidemiological studies 
published between 1998 and 2008 shows that light to 
moderate drinking is associated with a 38% lower risk of 
dementia and a 32% lower risk of developing Alzheimer's 
disease [48,49].  
Similar conclusions were reached by the meta-analysis 
of 15 studies, which revealed that light to moderate alcohol 
consumption in adulthood reduces the risk of dementia by 
47% compared to abstainers. Solfrizzi and co-authors 
monitored alcoholic patients with mild cognitive 
dysfunction, which is considered an early symptom of 
Alzheimer's disease. According to the observation, 
consuming up to 15g of alcohol per day reduces the rate of 
progression to dementia by approximately 85% [50]. 
Impressive in its scale is the prospective study by Zhang 
and co-workers, the results of which have been published 
recently [51]. A nationally representative sample of 1,887 
participants (with a mean age of 61.8 years) assessed the 
association of alcohol consumption and age-related decline 
in cognitive function, using multiple cognitive 
measurements, which have been carried out for 12 years. 
The data show that low to moderate alcohol use is 
associated with better general cognition and better results 
in specific cognitive domains – word recall, mental status, 
and vocabulary. Low to moderate drinking is also 
associated with a slower rate of cognitive decline in these 
domains.  
The findings are consistent with another study 
conducted among people living in a community (with a 
mean age of 73.2 years), where regular moderate alcohol 
consumption was associated with better cognitive function 
as compared to abstainers. Some of the prospective 
population-based studies have found a J-shaped, others a 
U-shaped curve in the link between alcohol consumption 
and the risk of cognitive dysfunction and dementia, which 
is considered evidence for the potential beneficial effects 
of moderate alcohol consumption [38,41,51-56]. This 
includes the cumulative effects of moderate alcohol 
consumption in youth and middle age – according to the 
data summarized by Stockley in 2015. Compared to 
abstainers, people who regularly consume moderate 
amounts of alcohol display higher scores in terms of 
attention stability, information processing speed, 
immediate or delayed word reproduction, recognition 
memory, working memory, and other cognitive 
dimensions. 
The topic of the type of alcohol consumed is worth 
considering, along with the potentially beneficial effects of 
moderate alcohol consumption. Moussa et al. (2015) report 
that long-term moderate alcohol use does neither 
exacerbate nor accelerate the natural course of age-related 
decline in cognitive function [53]. Similar conclusions are 
drawn by Huang et al. (2002) [54] who, in a prospective 
study of 402 residents of the Kungsholmen district in 
Stockholm, aged 75 and above, found that light to 
moderate alcohol consumption (wine, beer, or liquor) was 
associated with a reduced incidence of dementia and 
Alzheimer's disease. They hypothesize that this association 
may reflect a potentially protective effect of light to 
moderate alcohol consumption on the development of 
dementia and Alzheimer's disease; this effect may be 
attributed to alcohol per se, and cannot be related to the 
type of alcoholic beverages consumed.  
 However, based on the data from other publications, it 
can be assumed that "In vino veritas. i.e. In wine, there is 
truth". Neafsey and Collins, assessing the correlation 
between alcohol consumption and age-related decline in 
cognitive function, have found evidence for a beneficial 
effect of moderate alcohol consumption [55]. The analysis 
(based on the data from 14 countries) showed that wine has 
a more pronounced protective effect than beer and hard 
alcohol.  
Another prospective study on 2,613 men and women 
aimed at assessing the association between alcohol 
consumption (total and different types of beverages) and 
cognitive decline in middle age (assuming that slowing the 
rate of cognitive decline leads to the preservation of 
cognitive functioning in old age) [56]. The global cognitive 
function and specific domains such as memory, speed, and 
flexibility were assessed twice at 5-year intervals. It has 
been found that moderate intake of red wine is associated 
with the smallest decline in global cognitive function, 
memory, and cognitive flexibility (especially in women), 
while moderate use of other alcoholic beverages (more 
common in men) does not correlate with the rate of 
cognitive decline.  
These findings support the assumption that the non-
alcoholic substances in red wine are most likely 
responsible for the cognitive preserving effect (see the next 
section). The beneficial effect of wine is also confirmed by 
the results of a study including 980 individuals aged 65 and 
above without dementia at baseline [57].  After 4 years of 
follow-up, 260 people developed dementia, (199 of them 
developed Alzheimer's disease). The analysis of alcohol 
use and habits of the persons led the authors to the 
conclusion that the consumption of up to three servings of 
wine daily (33 g of alcohol) is associated with a lower risk 
of developing Alzheimer's disease. According to a study 
assessing the association between average alcoholic intake 
and cognitive performance in 15,807 patients, daily alcohol 
consumption of less than 40 g for women and 80 g or less 
for men is associated with a decreased probability of 
cognitive impairment [58].      




Table 1. Excerpts from the cited reference list regarding drinking categories/doses and beneficial/not 
harmful/harmful effects of alcohol. 
Reference Drinking categories and doses Findings 
Huang et al.,  
Ref № [54] 
Nondrinker: <1 unit per week (1 standard unit 
= 8 g ethanol). 
 
Light to moderate drinker: 1–21 units per week 
for men, or 1–14 units per week for women. 
 
Excessive drinker: >21 units per week for men, 
or >14 units per week for women. 
Light to moderate alcohol consumption is 
associated with a decreased incidence of 
dementia and Alzheimer’s disease. 
Solfrizzi et al.,  
Ref № [50] 
No alcohol intake. 
 
≤1 drink per day (approximately 15 g of 
alcohol). 
 
1 or more drinks but ≤2 drinks per day. 
 
>2 drinks per day. 
Patients with mild cognitive impairment who 
are moderate drinkers (who consumed 1.0 to 
14.9 g of alcohol per day, derived mostly 
from wine) have a lower rate of progression 
to dementia than the non-drinkers. 
Moussa  et al.,  
Ref № [53] 
 
 
Light alcohol consumption: 1–8 drinks per 
month (not exceeding two drinks per week). 
 
Moderate alcohol consumption: 7–21 drinks 
per week (not exceeding three drinks per day). 
 
Standard drink sizes: 12 oz glass (beer), 5 oz 
glass (wine), 1.5 oz glass (hard liquor). 
There is no evidence to support the idea that 
long-term moderate alcohol consumption in 
older adults exacerbates age-related cognitive 
decline. 
Kim et al.,      




Mild drinking: <1 standard drink per week 
(<10 g of pure alcohol per week). 
 
Moderate drinking: 1–13 standard drinks per 
week (10–130 of pure alcohol per week). 
 
Unsafe drinking: 14+ standard drinks per week 
(≥140 g of pure alcohol per week).  
Moderate lifetime alcohol intake is 
associated with lower cerebral Aβ deposition 
compared to a lifetime history of not drinking 
in middle- and old-aged individuals with 
neither dementia nor alcohol-related 
disorders. 
Siddiquee et al.,  
Ref № [97] 
Very light drinkers: <14 g ethanol per day. 
 
Light drinkers: 14–23 g ethanol per day. 
 
Moderate drinkers: >23–46 g ethanol per day. 
 
Heavy drinkers: >46 g ethanol per day. 
The results obtained do not suggest any 
beneficial or adverse relationship between 
the alcohol consumption levels and cognitive 
functioning in current elderly drinkers over 
that in never-drinkers. 
Zhang et al.,  
Ref № [51] 
Low to moderate drinkers: <8 drinks per week 
for women and <15 drinks per week for men. 
 
Heavy drinkers: ≥8 drinks per week for women 
and ≥15 drinks per week for men. 
Low to moderate drinking is associated with 
a consistently high cognitive function 
trajectory and a lower rate of cognitive 
decline. 
 
Reale et al., 
Ref № [38] 
Consumption of alcohol between 1 and 14 units 
per week (1 unit = 10 mL or 8 g pure alcohol). 
 
 
Consumption of alcohol >14 units per week. 
There is no evidence that the consumption of 
alcohol between 1 and 14 units per week 
increases the risk of dementia. 
 
Consumption of alcohol >14 units per week 
linearly increases the risk of dementia with 
age.   
Biological mechanisms of the potential protective effect 
of alcoholic beverages on cognitive aging and 
dementia 
Although there is evidence that the moderate 
consumption of any type of alcoholic beverage may have a 
protective effect on cognitive aging, wine is particularly 
suitable for discussing the biological mechanisms of this 
effect due to its rich composition of biologically active 
substances. More than 500 compounds have been identified 
in the fruit and wine of Vitis vinifera (grapevine) [41]. Wine 
 Margarita Velikova et al.  
 10 
contains alcohol, the largest amount being ethanol. The 
concentration of ethanol in table wines usually varies 
between 8 and 15 volume percent [59]. The main 
difference between wine and other alcoholic beverages is 
that wine contains phenolic compounds similar to those 
found in fruits, vegetables, and tea, the consumption of 
which is associated with a lower incidence of mild 
cognitive dysfunction, dementia, and other cerebrovascular 
neurodegenerative diseases. Wine contains two main 
classes of phenolic compounds: flavonoids and non-
flavonoids. Their relative content depends on several 
factors such as the grape variety, climatic conditions, soil 
type and the type of cultivation, wine production 
technology, and wine aging. The main polyphenols in wine 
are flavanols, flavonols, anthocyanins, and resveratrol. 
Flavonoids include catechin, epicatechin, 
proanthocyanidins, flavones, and anthocyanins. Myricetin, 
kaempferol, rutin, and quercetin are representatives of 
flavonols. Delphinidin-3-glucoside, cyanidin-3-glucoside, 
and malvidin-3-glucoside are the most common 
anthocyanins in wine [38]. Some of the most important 
flavonoids in wine are anthocyanins, flavanols (catechins 
or flavan-3-ols), and flavonols (quercetin and myricetin); 
the group also includes proanthocyanidins, dimers, and 
oligomers of catechin and epicatechin and their gallic acid 
esters. Non-flavonoids are different classes of compounds 
that are substituted phenols. These include benzoic acid 
derivatives (vanillic and gallic), benzaldehydes (vanillin 
and syringe aldehyde), cinnamic acids (para-coumaric, 
ferulic, caffeic), and cinnamon aldehydes (mustard 
aldehyde) [60]. Non-phenolic compounds that contribute 
to the antioxidant activity of wine are ascorbic acid and 
sulfur dioxide [61]. Their natural content in wine is very 
small, but they are often added in the winemaking process. 
Sulfur dioxide inactivates the enzyme polyphenol oxidase 
[62], which is responsible for the oxidation of phenolic 
compounds, and thus contributes to the preservation of the 
polyphenolic content and antioxidant activity of wine. 
 Resveratrol is an important compound in wine with 
beneficial health effects. It is a natural phytoalexin that is 
produced by some plants in response to damage [63]. 
Resveratrol belongs to the class of organic compounds 
(stilbenes) and it is found in nature in two isoforms (i.e. cis- 
and trans-), the trans isoform being biologically active. 
Both isoforms are synthesized in the skin of grapes and 
reach maximum concentration before ripening. Stilbene 
synthase, the key enzyme in resveratrol biosynthesis, is 
activated by exogenous factors such as stress, UV light, 
chemical signals, and pathogens. Red grapes and red wine 
contain about 3 to 10 times more resveratrol than white 
ones, with an average trans-resveratrol content of 1.9 - 1.7 
mg/L. According to our data, the highest polyphenolic 
content is found in red wines (average of 567 ± 32 mg/L), 
followed by rosé (323 ± 84 mg/L) and white wines (281 ± 
42 mg/L) [64]. The data from animal studies reveal that 
phenolic compounds derived from grapes and wine are 
absorbed, cross the blood-brain barrier, and accumulate in 
the brain. Alcohol also plays an important role by 
promoting their absorption and thus increasing their 
bioavailability [65]. 
 At present, it is difficult to state whether the possible 
health benefits of wine are due to ethanol, its micro-
components, or to their synergistic effect. The complex 
beneficial effect of phenolic compounds and ethanol on the 
risk of cardiovascular and cerebrovascular diseases can be 
associated with changes in the lipid profile, hemostasis, 
and circulation [66]. In particular, an ethanol-induced 
increase in HDL-cholesterol concentration (which is 
inversely correlated with the risk of cardiovascular 
disorder) has been reported. Light alcohol intake was 
associated with an increased activity of tissue plasminogen 
activator and decreased levels of plasma coagulation 
factors such as fibrinogen, proconvertin, and von 
Willebrand factor [67,68]. All these changes are associated 
with a reduced risk of atherosclerosis, Alzheimer's disease, 
and vascular dementia. The results obtained from human 
studies reveal that moderate alcohol intake is protective 
against vascular changes and atrophy in the brain, and 
ischemic brain injury [69].  From the above data, it can be 
concluded, that the main ingredients of wine will work 
against dementia and in favor of the cognitive functions, by 
counteracting atherosclerosis and protecting the brain from 
ischemia. 
 As previously mentioned, brain aging and cognitive 
decline are associated with oxidative stress, inflammation, 
mitochondrial dysfunction, and brain insulin resistance. In 
this regard, it is important to note that resveratrol can lower 
ROS by down-regulating enzymes such as xanthine 
oxidase, involved in the production of ROS and up-
regulating endogenous antioxidant enzymes (superoxide 
dismutase, glutathione peroxidase, catalase, heme 
oxygenase) [70,71]. Resveratrol can counteract the 
production of mitochondrial ROS, resulting in increased 
mitochondrial activity and bioenergetic efficiency. It is 
considered that the inhibition of the ATP synthase by 
resveratrol might play a significant role in the 
pathophysiology of neurological disorders and aging [72]. 
Resveratrol modulates the activity of sirtuin 1 (SIRT1) and 
thus the regulation of p53, a key protein involved in DNA 
repair [73]. As a ligand of leukotriene A4 hydrolase, 
resveratrol exhibits anti-inflammatory and antioxidant 
activity [74]. The data оn the ability of its analogs to reduce 
insulin resistance by improving energy homeostasis is 
intriguing given the reduced insulin effectiveness, 
accompanying brain aging [75].  Experiments have 
demonstrated the neuroprotective effects of resveratrol, as 
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well as the positive effects on cognitive functions, learning, 
memory, and depressive state [76,77]. 
 Red wine is a rich source of polyphenolic antioxidants 
such as flavonols (quercetin) and flavonoids 
(anthocyanins). Acting as an antioxidant, quercetin is 
capable of effectively removing ROS [78] and may have a 
protective effect in Alzheimer's disease and oxidative 
stress-related neurodegenerative diseases. Quercetin exerts 
neuroprotective effects against the toxic molecules by 
modulating the mechanisms of cell death, increasing the 
resistance of neurons to oxidative stress, inhibiting the 
inducible nitric oxide synthase (iNOS), regulating 
cyclooxygenase-2 (COX-2), and exerting the anti-
inflammatory activity [38]. The anthocyanins also exhibit 
antioxidant and anti-inflammatory effects by inhibiting 
inflammatory enzymes such as iNOS and COX-1 [79]. 
Oligonol, extracted from grape seeds and part of Vitis 
vinifera must also be added to the polyphenol list with 
antioxidant and anti-inflammatory effects [38, 80]. Since 
oxidative stress and inflammation are linked to 
neurodegeneration, the polyphenols in wine may exert 
protective effects against neurodegenerative diseases. 
 What are the beneficial effects of wine ingredients in 
the pathogenesis of Alzheimer's disease? This 
neurodegenerative disease is characterized by amyloid-β 
(Aβ) deposits and the accumulation of plaques in the brain. 
Recently, Kim et al. (2020) have published some data that 
moderate alcohol consumption throughout life is 
associated with lower Aβ deposition in the brain as 
compared to abstainers in middle-aged and elderly 
individuals [69]. Aβ peptide is generated by proteolytic 
cleavage of amyloid precursor protein (APP) by alpha, 
beta, and gamma secretases. Unlike alpha-secretase, which 
cleaves APP to the non-toxic amyloid alpha, toxic Aβ is 
derived by the sequential action of beta and gamma 
secretases. The most common isoforms that are produced 
are Aβ40 and Aβ42. In experiments with transgenic mice 
Tg2576 (an animal model of Alzheimer's disease), it was 
found that the administration of red wine in doses 
equivalent to two standard drinks leads to non-
amyloidogenic processing of APP and thus prevents Aβ 
production. The levels of amyloidogenic Aβ1-40 and Aβ1-
42 in the neocortex and the hippocampus of mice were 
decreased, while the alpha-secretase activity was increased 
[81]. Resveratrol in red wine has been shown to have 
beneficial effects on the pathogenesis of Alzheimer's 
disease by affecting some molecular mechanisms of the 
amyloid cascade. It lowers intracellular Aβ levels by 
inhibiting the formation of Aβ fibrils and promoting 
autophagic and lysosomal degradation of Aβ, it reduces 
tau-phosphorylation and deposition, as well as Aβ-induced 
ROS production [41,82]. Other polyphenols also 
demonstrated beneficial effects on the pathogenesis of 
Alzheimer's disease: quercetin inhibits Aβ synthesis, and 
epigallocatechin-3-gallate modulates APP processing by 
acting on the non-amyloidogenic α-secretase pathway and 
counteracting Aβ-induced oxidative stress [38]. Aβ 
aggregation has been recognized as a necessary condition 
for Aβ-neurotoxicity. In vitro and animal studies have 
shown that grape-seed derived polyphenolics (containing 
mostly catechin and epicatechin) prevent Aβ 
oligomerization and reduce the cognitive impairment in a 
model with Alzheimer's disease [83]. 
 Protein kinase C (PKC) is a family of protein kinase 
enzymes, involved in signal transduction pathways; it is 
also important in memory processes and learning [84]. 
PKC modulates APP processing and can reduce the 
accumulation of pathogenic Aβ in the brain [85]. 
Resveratrol and epigallocatechin-3-gallate have been 
reported to protect hippocampal neurons from Aβ-induced 
toxicity by activating PKC [41]. 
 Studies reveal changes in specific neurotransmitter 
systems with normal aging and more deficits in dementia. 
Severe loss of cholinergic neurons in the nucleus basalis is 
a feature of Alzheimer's disease [86]. There is a reason to 
believe that the impaired cholinergic neurotransmission 
may also contribute to the formation of amyloid fibrillar 
plaques. In this regard, it is worth noting that ethanol (in 
low concentrations) can stimulate the release of 
acetylcholine in the hippocampus with a positive effect on 
cognitive functions [66]. This may explain the observation 
that drinking small amounts of alcohol improves the 
memory of the events that occurred before consumption in 
healthy individuals [87]. There is also evidence that 
acetylcholine levels may be positively affected by 
catechins (epigallocatechin-3-gallate), which act as 
acetylcholinesterase inhibitors [88]. The inhibition of 
acetylcholinesterase contributes to the restoration of 
cholinergic neurotransmission and appears to prevent the 
aggregation of amyloid-β peptides and the formation of 
amyloid fibrillar plaques [89]. 
 A study on the effect of ethanol on the kinetics of β-
amyloid aggregation in vitro revealed that ethanol prevents 
the formation of stable Aβ dimers in vitro, thus protecting 
the cells maintained in culture [90]. The research of Bate 
and Williams on the effects of ethanol on cultured cortical 
and hippocampal neurons provides evidence that moderate 
alcohol consumption prevents dementia in Alzheimer's 
disease.  Ethanol administered in physiologically relevant 
concentrations of 0.02–0.08% protected neurons against 
the synapse damage induced by Aβ42, a neurotoxin 
responsible for memory defects occurring in Alzheimer's 
disease [91]. 
While looking for approaches to counteract the 
neurodegenerative processes in the brain associated with 
oxidative damage as a result of high ROS production 
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(generated, for example, by neurotoxic agents such as Aβ), 
scientists have recently discovered the potential of 
neurotrophins [92]. The brain-derived neurotrophic factor 
(BDNF) is known to be a key regulator of neuronal 
plasticity and development. Upon binding to its receptor, 
BDNF activates a transduction-signaling pathway that is 
common to the process of stimulating cell proliferation 
and/or inhibiting the apoptosis cascade. Accordingly, it is 
interesting to point out that moderate alcohol consumption 
increases BDNF levels [93]. Regarding neurotrophins, 
vitamin D is worth being mentioned again, because it 
exerts its multifaceted neuroprotective effects by 
regulating the synthesis of neurotrophins. Several studies 
on humans presented data that alcohol consumption is 
positively associated with vitamin D status and reduced 
risk of vitamin D deficiency [94-96]. The mechanism by 
which alcohol can affect serum vitamin D concentrations 
is unclear at the moment, but the effects should not be 
overlooked when talking about alcohol consumption, 
neuroprotection, and cognitive well-being. 
Highlights 
✓ Prospective population-based studies have revealed a 
J-shaped or a U-shaped curve in the link between 
alcohol consumption and the risk of cognitive 
dysfunction and dementia, which is considered 
evidence for the potential beneficial effects of 
moderate alcohol consumption. 
✓ The more common opinion is that red wine has a more 
pronounced protective effect than other alcoholic 
beverages. 
✓ The main ingredients of wine act against dementia and 
in favor of the cognitive functions because phenolic 
compounds and ethanol exhibit anti-inflammatory and 
antioxidant activity, and reduce insulin resistance, 
inhibit Aβ synthesis and lower the intracellular Aβ 
levels, tau-phosphorylation, and amyloid plaque 
deposition, thus counteracting the Aβ-induced 
synaptic damage. 
Conclusions 
The data presented in this article reveal only a small 
part of the discussion on the potentially beneficial effects 
of moderate alcohol consumption on cognitive aging and 
dementia, and the biological mechanisms of the beneficial 
effects of alcohol and alcoholic beverages. Further research 
is needed to confirm the data cited and to refute the other 
common opinions (supported by reports in the scientific 
literature) about the lack of beneficial effects of moderate 
alcohol consumption on the cognitive functions in the 
aging process [97-100].  
Conflict of interest disclosure 
There are no known conflicts of interest in the 
publication of this article. The manuscript was read and 
approved by all authors. 
Compliance with ethical standards 
Any aspect of the work covered in this manuscript has 
been conducted with the ethical approval of all relevant 
bodies and that such approvals are acknowledged within 
the manuscript.  
References 
1. Arora BP. Anti-aging medicine. Indian J Plast Surg. 
2008; 41(Suppl):  S130–S133. 
2. Lipsitz LA. Aging as a process of complexity loss. In: 
Thomas S. Deisboeck and J. Yasha Kresh (Eds.) 
Complex Systems Science in Biomedicine, Springer, 
2006; pp. 641–654. ISBN: 978-0-387-33532-2 
3. Libertini G. Aging Definition. In: D. Gu and M. E. 
Dupre (Eds.) Encyclopedia of Gerontology and 
Population Aging. Springer Nature Switzerland AG, 
2019; doi: 10.1007/978-3-319-69892-2_29-1 
4. Vauzour D, Camprubi-Robles M, Miquel-Kergoat 
S, Andres-Lacueva C, Bánáti D,  Barberger-Gateau P,  
Bowman GL, Caberlotto L, Clarke R, Hogervorst 
E,  Kiliaan AJ, Lucca U, Manach C,  Minihane 
A,  Mitchell ES, Perneczky R, Perry H,  Roussel 
A, Schuermans J, Sijben J,  Spencer JP, Thuret S, van 
de Rest O, Vandewoude M, Wesnes K,  Williams 
RJ,  Williams RS, Ramirez M. Nutrition for the ageing 
brain: Towards evidence for an optimal diet. Ageing 
Res Rev. 2017; 35: 222–240.  
doi: 10.1016/j.arr.2016.09.010 
5. Medvedev ZA. An attempt at a rational classification of 
theories of ageing. Biol Rev Camb Philos Soc. 1990; 
65(3):375-98.  
doi: 10.1111/j.1469-185x.1990.tb01428.x 
6. Sergiev PV, Dontsova OA, Berezkin GV. Theories of 
aging: an ever-evolving field. Acta Naturae. 2015; 
7(1): 9–18. doi: 10.32607/20758251-2015-7-1-9-18 
7. Harman D. The free radical theory of aging. Antioxid 
Redox Signal. 2003; 5(5): 557–561. doi: 
10.1089/152308603770310202 
8. Tosato M, Zamboni V, Ferrini A, Cesari M. The aging 
process and potential interventions to extend life 
expectancy. Clin Interv Aging. 2007;2(3):401–412. 
9. Jin K. Modern biological theories of aging. Aging Dis. 
2010, 1(2): 72–74. 
10. Cesari M, Kritchevsky SB, Leeuwenburgh C, Pahor M. 
Oxidative damage and platelet activation as new 
predictors of mobility disability and mortality in elders. 
Antioxid Redox Signal. 2006; 8(3-4): 609–619. doi: 
10.1089/ars.2006.8.609 
Alcohol consumption, cognitive aging, benefits? 
 13 
11. Franceschi C, Bonafè M, Valensin S, Olivieri F, De 
Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. 
An evolutionary perspective on immunosenescence. 
Ann NY Acad Sci. 2000; 908: 244–254. doi: 
10.1111/j.1749-6632.2000. tb06651.x 
12. Franceschi C, Valensin S, Bonafe M,  Paolisso 
G,  Yashin AI,  Monti D, De Benedictis G. The network 
and remodeling theories of aging: historical 
background and new perspectives. Exp Gerontol. 2000; 
35(6-7): 879–896.  
doi: 10.1016/S0531-5565(00)00172-8 
13. Anderson LW, Krathwohl DR. A Taxonomy for 
Learning, Teaching and Assessing: A Revision of 
Bloom's Taxonomy of Educational Objectives. New 
York: Longman Publishing, 2001. 
14. Dietrich A. The cognitive neuroscience of creativity. 
Psychon Bull Rev. 2004; 11: 1011-1026. doi: 
org/10.3758/BF03196731 
15. Craft S, Cholerton B, Baker LD. Insulin and 
Alzheimer's disease: untangling the web. J Alzheimers 
Dis. 2013; 33(Suppl 1): S263–S275. doi: 10.3233/JAD-
2012-129042     
16. Calvo-Ochoa E, Arias C. Cellular and metabolic 
alterations in the hippocampus caused by insulin 
signaling dysfunction and its association with cognitive 
impairment during aging and Alzheimer's disease: 
studies in animal models. Diabetes Metab Res Rev. 
2015; 31(1): 1–13. doi: 10.1002/dmrr.2531 
17. Williamson R, McNeilly A, Sutherland C. Insulin 
resistance in the brain: anold-age or new-age problem? 
Biochem Pharmacol. 2012; 84(6): 737–745. doi: 
10.1016/j.bcp.2012.05.007 
18. Kandimalla R., Thirumala V, Hemachandra P. Is 
Alzheimer's disease a Type 3 Diabetes? A critical 
appraisal. Biochim Biophys Acta Mol Basis Dis. 2017; 
1863(5): 1078–1089.  
doi: 10.1016/j.bbadis.2016.08.018 
19. Gold J, Shoaib A, Gorthy G, Grossberg GT. The role of 
vitamin D in cognitive disorders in older adults. US 
Neurology. 2018;14(1):41–46.  
doi: 10.17925/USN.2018.14.1.41 
20. Rimmelzwaan LM, van Schoor NM, Lips P, Berendse 
HW, Eekhoff EM. Systematic review of the 
relationship between vitamin D and Parkinson's 
disease. J Parkinsons Dis. 2016; 29(6): 29-37. doi: 
10.3233/JPD-150615  
21. Shen L, Ji HF. Vitamin D deficiency is associated with 
increased risk of Alzheimer's disease and dementia: 
evidence from meta-analysis. Nutr J. 2015; 14: 76. doi: 
10.1186/s12937-015-0063-7 
22. Baas D, Prüfer K, Ittel ME, Kuchler-Bopp S, 
Labourdette G, Sarliève LL, Brachet P. Rat 
oligodendrocytes express the vitamin D(3) receptor and 
respond to 1,25-dihydroxyvitamin D(3). Glia. 2000; 
31(1): 59–68. doi: 10.1002/(sici)1098-
1136(200007)31:1<59:aid-glia60>3.0.co;2-y 
23. Wang JY, Wu JN, Cherng TL, Hoffer BJ, Chen HH, 
Borlongan CV, Wang Y. Vitamin D(3) attenuates 6-
hydroxydopamine-induced neurotoxicity in rats. Brain 
Res. 2001; 904(1): 67–75. doi: 10.1016/s0006-
8993(01)02450-7 
24. Gezen-Ak D, Dursun E, Yilmazer S. The effects of 
vitamin D receptor silencing on the expression of 
LVSCC-A1C and LVSCC-A1D and the release of 
NGF in cortical neurons. PLoS One. 2011; 6(3): 
e17553. doi: 10.1371/ journal.pone.0017553 
25. Brewer LD, Thibault V, Chen KC, Langub MC, 
Landfield PW, Porter NM. Vitamin D hormone confers 
neuroprotection in parallel with downregulation of L-
type calcium channel expression in hippocampal 
neurons. J Neurosci. 2001; 21(1): 98–108. doi: 
10.1523/JNEUROSCI.21-01-00098.2001 
26. Garcion E, Wion-Barbot N, Montero-Menei CN, 
Berger F, Wion D. New clues about vitamin D 
functions in the nervous system. Trends Endocrinol 
Metab. 2002; 13(3): 100–105. doi: 10.1016/s1043-
2760(01)00547-1 
27. Banerjee A, Khemka VK, Ganguly A, Roy D, Ganguly 
U, Chakrabarti S. Vitamin D and Alzheimer's disease: 
neurocognition to therapeutics. Int J Alzheimers Dis. 
2015; 2015:192747. doi: 10.1155/2015/192747 
28. Annweiler C, Beauchet O. Vitamin D-mentia: 
randomized clinical trials should be the next step. 
Neuroepidemiology. 2011; 37(3-4): 249–258. doi: 
10.1159/000334177  
29. Chakrabarti S, Munshi S, Banerjee K, Thakurta IG, 
Sinha M, Bagh MB. Mitochondrial dysfunction during 
brain aging: role of oxidative stress and modulation by 
antioxidant supplementation. Aging Dis. 2011; 2(3): 
242–256.   
30. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X. 
Oxidative stress and mitochondrial dysfunction in 
Alzheimer’s disease. Biochim Biophys Acta. 2014; 
1842(8): 1240–1247.  
doi: 10.1016/j.bbadis.2013.10.015 
31. Perry VH, Holmes C.  Microglial priming in 
neurodegenerative disease. Nat Rev Neurol. 2014; 
10(4): 217–224. doi: 10.1038/nrneurol.2014.38 
32. Perry VH. The influence of systemic inflammation on 
inflammation in the brain: implications for chronic 
neurodegenerative disease. Brain Behav Immun. 2004; 
18(5): 407–413. doi: 10.1016/j.bbi.2004.01.004 
33. Perry VH, Cunningham C, Holmes C. Systemic 
infections and inflammation affect chronic 
neurodegeneration. Nat Rev Immunol. 2007; 7(2): 161–
167. doi: 10.1038/nri2015 
34. Giaccone G, Arzberger T, Alafuzoff I, Al-Sarraj S, 
Budka H, Duyckaerts C, Falkai P, Ferrer I, Ironside JW, 
 Margarita Velikova et al.  
 14 
Kovacs GG, Meyronet D, Parchi P, Patsouris E, Revesz 
T, Riederer P, Rozemuller A, Schmitt A, Winblad B, 
Kretzschmar H. New lexicon and criteria for the 
diagnosis of Alzheimer’s disease. Lancet Neurol. 2011; 
10(4): 298–299. doi: 10.1016/S1474-4422(11)70055-2 
35. Jack Jr. CR, Albert MS, Knopman DS, McKhann GM, 
Sperling RA, Carrillo MC, Thies B, Phelps CH. 
Introduction to the recommendations from the National 
Institute on Aging-Alzheimer’s Association 
workgroups on diagnostic guidelines for Alzheimer’s 
disease. Alzheimers Dement. 2011; 7(3): 257–262. doi: 
10.1016/j.jalz.2011.03.004 
36. Blennow K, Hampel H, Weiner M, Zetterberg H. 
Cerebrospinal fluid and plasma biomarkers in 
Alzheimer disease. Nat Rev Neurol. 2010; 6(3): 131–
144. doi: 10.1038/nrneurol.2010.4 
37.  Perneczky R, Alexopoulos P, Kurz A. Soluble amyloid 
precursor proteins and secretases as Alzheimer’s 
disease biomarkers. Trends Mol Med. 2014; 20(1): 8–
15. doi: 10.1016/j.molmed.2013.10.001 
38. Reale M, Costantini E, Jagarlapoodi S, Khan H, Belwal 
T, Cichelli A. Relationship of wine consumption with 
Alzheimer’s disease. Nutrients. 2020; 12(1): 206. doi: 
10.3390/nu12010206. 
39. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni 
L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang 
Y, Jorm A, Mathers C, Menezes PR, Rimmer E, 
Scazufca M, Alzheimer’s Disease International. Global 
prevalence of dementia: A Delphi consensus study. 
Lancet. 2005; 366(9503): 2112–2117. doi: 
10.1016/S0140-6736(05)67889-0 
40. Butler RN, Fossel M, Harman M, Heward CB, 
Olshansky SJ, Perls TT, Rothman DJ, Rothman SM, 
Warner HR, West MD, Wright WE. Is there an 
Antiaging Medicine? J Gerontol A Biol Sci Med Sci. 
2002; 57(9): B333–B338.  
doi: 10.1093/gerona/57.9.b333 
41. Stockley CS. Wine consumption, cognitive function 
and dementias – A relationship? Nutr Aging (Amst). 
2015; 3(2-4): 125–137. doi: 10.3233/NUA-150055 
42. Cao L, Tan L, Wang HF, Jiang T, Zhu XC, Lu H, Tan 
MS, Yu JT. Dietary patterns and risk of dementia: a 
systematic review and meta-analysis of cohort studies. 
Mol Neurobiol. 2016; 53(9): 6144–6154. doi: 
10.1007/s12035-015-9516-4 
43. McEvoy CT, Hoang T, Sidney S, Steffen LM, Jacobs 
DR Jr, Shikany JM, Wilkins JT, Yaffe K. Dietary 
patterns during adulthood and cognitive performance in 
midlife: The CARDIA study. Neurology. 2019; 92(14): 
e1589–e1599. doi:10.1212/WNL.0000000000007243  
44. Bach-Faig A, Berry EM, Lairon D, Reguant J, 
Trichopoulou A, Dernini S, Medina FX, Battino M, 
Belahsen R, Miranda G, Serra-Majem L, 
Mediterranean Diet Foundation Expert Group. 
Mediterranean diet pyramid today. Science and cultural 
updates. Public Health Nutr. 2011; 14(12А): 2274–
2284. doi: 10.1017/S1368980011002515 
45. Robinson J. (Еd). The Oxford Companion to Wine (3rd 
ed.), Oxford University Press, 2006, pp. 433. 
46. Liappas JA, Lascaratos J, Fafouti S, Christodoulou GN. 
Alexander the Great's relationship with alcohol. 
Addiction. 2003;98(5):561-7. doi: 10.1046/j.1360-
0443.2003.00384.x 
47. Karbowiak T, Crouvisier-Urion K, Lagorce A, 
Ballester J, Geoffroy A, Roullier-Gall C, Chanut J, 
Gougeon RD, Schmitt-Kopplin P, Bellat JP. Wine 
aging: a bottleneck story. NPJ Sci Food. 2019;3:14. 
doi: 10.1038/s41538-019-0045-9 
48. Peters R, Peters J, Warner J, Beckett N, Bulpitt C. 
Alcohol, dementia and cognitive decline in the elderly: 
A systematic review. Age Ageing. 2008; 37(5): 505-
512. doi: 10.1093/ageing/afn095 
49. Anstey KJ, Mack HA, Cherbuin N. Alcohol 
consumption as a risk factor for dementia and cognitive 
decline: meta- analysis of prospective studies. Am J 
Geriatr Psychiatry. 2009; 17(7): 542–555. doi: 
10.1097/JGP.0b013e3181a2fd07 
50. Solfrizzi V, D’Introno A, Colacicco AM, Capurso C, 
Gagliardi G, Santamato A, Baldassarre G, Capurso A, 
Panza F. Lifestyle-related factors, alcohol 
consumption, and mild cognitive impairment. J Am 
Geriatric Soc. 2007; 55(10): 1679–1681. doi: 
10.1111/j.1532-5415.2007.01313.x 
51. Zhang R, Shen L, Miles T, Shen Y, Cordero J, Qi Y, 
Liang L, Li C. Association of low to moderate alcohol 
drinking with cognitive functions from middle to older 
age among US adults. JAMA Netw Open. 2020; 3(6): 
e207922. doi:10.1001/jamanetworkopen.2020.7922 
52. Richard EL, Kritz-Silverstein D, Laughlin GA, Fung 
TT, Barrett-Connor E, McEvoy LK. Alcohol intake and 
cognitively healthy longevity in community-dwelling 
adults: The Rancho Bernardo Study. J Alzheimers Dis. 
2017; 59(3): 803–814. doi: 10.3233/JAD-161153 
53. Moussa MN, Simpson SL, Mayhugh RE, Grata ME, 
Burdette JH, Porrino LJ, Laurienti PJ. Long-term 
moderate alcohol consumption does not exacerbate 
age-related cognitive decline in healthy, community-
dwelling older adults. Front Aging Neuroscience. 
2015;6: 341. doi: 10.3389/fnagi.2014.00341  
54. Huang W, Qiu C, Winblad B, Fratiglioni L. Alcohol 
consumption and incidence of dementia in a 
community sample aged 75 years and older. J Clin 
Epidemiol. 2002; 55(10): 959–964. doi: 
10.1016/S0895-4356(02)00462-6 
55. Neafsey EJ, Collins MA. Moderate alcohol 
consumption and cognitive risk. Neuropsychiatr Dis 
Treat. 2011; 7: 465–484. doi: 10.2147/NDT.S23159 
Alcohol consumption, cognitive aging, benefits? 
 15 
56. Nooyens ACJ, Bueno-de-Mesquita HB, van Gelder 
BM, van Boxtel MPJ, Verschuren WMM. 
Consumption of alcoholic beverages and cognitive 
decline at middle age: the Doetinchem Cohort Study. 
Br J Nutr. 2014; 111(4): 715–723. doi: 
10.1017/S0007114513002845 
57. Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux 
R. Alcohol intake and risk of dementia. J Am Geriatric 
Soc. 2004; 52(4): 540–546. doi: 10.1111/j.1532-
5415.2004.52159.x 
58. Zuccala G, Onder G, Pedone C, Cesari M, Landi F, 
Bernabei R, Cocchi A. Dose-related impact of alcohol 
consumption on cognitive function in advanced age: 
results of a multicenter survey. Alcohol Clin Exp Res. 
2001; 25(12): 1743–1748. 
59. Bao Q, Zhao H, Han S, Zhang C, Hasi W. Surface-
enhanced Raman spectroscopy for rapid identification 
and quantification of Flibanserin in different kinds of 
wine. Anal Methods. 2020;12(23):3025-3031. doi: 
10.1039/d0ay00741b 
60. Cassino C, Gianotti V, Bonello F, Tsolakis C, Cravero 
M, Osella D. Antioxidant composition of a selection of 
Italian red wines and their corresponding free-radical 
scavenging ability. J Chem. 2016; 3: 1–8. doi: 
10.1155/2016/4565391 
61. Barril C, Clark AC, Scollary GR. Chemistry of ascorbic 
acid and sulfur dioxide as an antioxidant system 
relevant to white wine. Anal Chim Acta. 2012; 732: 
186–193. doi: 10.1016/j.aca.2011.11.011 
62. Coetzee C, Lisjak K, Nicolau L, Kilmartin P, du Toit 
WJ. Oxygen and sulfur dioxide additions to Sauvignon 
blanc must: effect on must and wine composition. 
Flavour Fragr J. 2013; 28(3): 155–167. doi: 
10.1002/ffj.3147 
63. Porro C, Cianciulli A, Calvello R, Panaro MA. 
Reviewing the role of resveratrol as a natural modulator 
of microglial activities. Curr Pharm Des. 2015; 21(36): 
5277–5291. 
doi:10.2174/1381612821666150928155612 
64. Todorova MN, Pasheva MG, Kiselova-Kaneva YD, 
Ivanova DG, Galunska BTz. Phenolics content and 
antioxidant activity of beverages on the Bulgarian 
market – wines, juices and compotes. Bulg Chem 
Commun. 2018; 50: 164–168. 
65. Weiskirchen S, Weiskirchen R. Resveratrol: how much 
wine do you have to drink to stay healthy? Adv Nutr. 
2016;7(4):706–718. doi: 10.3945/an.115.011627 
66. Wiegmann C, Mick I, Brandl EJ, Heinz A, Gutwinski 
S. Alcohol and dementia – what is the link? A 
systematic review. Neuropsychiatr Dis Treat. 2020;16: 
87–99. doi: 10.2147/NDT.S198772 
67. Tabengwa EM, Grenett HE, Benza RL, Abou-Agag 
LH, Tresnak JK, Wheeler CG, Booyse FM. Ethanol-
induced up-regulation of the urokinase receptor in 
cultured human endothelial cells. Alcohol Clin Exp Res. 
2001;25(2):163–170.  
68. Lee KW, Lip GYH.  Effects of lifestyle on hemostasis, 
fibrinolysis, and platelet reactivity: a systematic 
review. Arch Intern Med. 2003;163(19): 2368-2392. 
doi: 10.1001/archinte.163.19.2368 
69. Kim JW, Byun MS, Yi D, Lee JH, Ko K, Jeon SY, Sohn 
BK, Lee JY, Kim YK, Shin SA, Sohn CH, Lee DY, 
KBASE Research Group. Association of moderate 
alcohol intake with in vivo amyloid-beta deposition in 
human brain: a cross-sectional study. PLoS Med. 2020; 
17(2): e1003022. doi: 10.1371/journal.pmed.1003022 
70. Gerszon J, Rodacka A, Puchała M. Antioxidant 
properties of resveratrol and its protective effects in 
neurodegenerative diseases. Adv Cell Biol. 2014;4:97–
117. doi: 10.2478/acb-2014-0006 
71. Desquiret-Dumas V, Gueguen N, Leman G, Baron S, 
Nivet-Antoine V, Chupin S, Chevrollier A, Vessières 
E, Ayer A, Ferré M. Resveratrol induces a 
mitochondrial complex I-dependent increase in NADH 
oxidation responsible for sirtuin activation in liver 
cells. J Biol Chem. 2013;288(51):36662–36675. doi: 
10.1074/jbc.M113.466490 
72. Gledhill JR, Montgomery MG, Leslie AG, Walker JE. 
Mechanism of inhibition of bovine F1-ATPase by 
resveratrol and related polyphenols. Proc Natl Acad Sci 
USA. 2007; 104(34): 13632–13637. doi: 
10.1073/pnas.0706290104 
73. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, 
Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, 
Zhang LL, Scherer B, Sinclair DA. Small molecule 
activators of sirtuins extend Saccharomyces cerevisiae 
lifespan. Nature. 2003; 425: 191–196. doi: 
10.1038/nature01960 
74. Davies DR, Mamat B, Magnusson OT, Christensen J, 
Haraldsson MH, Mishra R, Pease B, Hansen E, Singh 
J, Zembower D, Kim H, Kiselyov AS, Burgin AB, 
Gurney ME, Stewart LJ. Discovery of leukotriene A4 
hydrolase inhibitors using metabolomics biased 
fragment crystallography. J Med Chem. 2009;52(15): 
4694–4715. doi: 10.1021/jm900259h 
75. Milne JC, Lambert PD, Schenk S, Carney DP, Smith 
JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB. Small 
molecule activators of SIRT1 as therapeutics for the 
treatment of type 2 diabetes. Nature. 2007;450(7170): 
712–716. doi:10.1038/nature06261 
76. Ge L, Liu L, Liu H, Liu S, Xue H, Wang X, Yuan L, 
Wang Z, Liu D. Resveratrol abrogates 
lipopolysaccharide-induced depressive-like behavior, 
neuroinflammatory response, and CREB/BDNF 
signaling in mice. Eur J Pharmacol. 2015;768:49–57. 
doi: 10.1016/j.ejphar.2015.10.026 
77. Ge JF, Xu YY, Li N, Zhang Y, Qiu GL, Chu CH, Wang 
CY, Qin G, Chen FH. Resveratrol improved the spatial 
 Margarita Velikova et al.  
 16 
learning and memory in subclinical hypothyroidism rat 
induced by hemi-thyroid electrocauterization. Endocr 
J. 2015;62(10):927–938. doi: 10.1507/endocrj.EJ15-
0253 
78. Chervenkov T, Gerova D, Galunska B, Enchev V. 
Theoretical and experimental evaluation of antioxidant 
potential of natural bioflavonoids rutin and quercetin: 
PP8C-9. FEBS J. 2008; 275(1): 377. 
79. Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, 
Sharifi-Rad M, Fokou PVT, Martins N, Sharifi-Rad J. 
Resveratrol: a double-edged sword in health benefits. 
Biomedicines. 2018; 6(3): 91. doi: 
10.3390/biomedicines6030091 
80. Bahijri SM, Ajabnoor G, Hegazy GA Alsheikh L, 
Moumena MZ, Bashanfar BM, Alzahrani AH. 
Supplementation with oligonol, prevents weight gain 
and improves lipid profile in overweight and obese 
saudi females. Curr Nutr Food Sci. 2018;14(2):164–
170. doi:10.2174/1573401313666170609101408 
81. Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein 
DL, Thiyagarajan M, Percival SS, Talcott ST, Pasinetti 
GM. Moderate consumption of Cabernet Sauvignon 
attenuates A beta neuropathology in a mouse model of 
Alzheimer’s disease. FASEB J. 2006;20(13):2313–
2320. doi: 10.1096/fj.06-6281com 
82. Marambaud P, Zhao H, Davies P. Resveratrol promotes 
clearance of Alzheimer’s disease amyloid-β peptides. J 
Biol Chem. 2005; 280(45): 37377–37382. doi: 
10.1074/jbc.M508246200 
83. Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen 
LH, Humala N, Teplow DB, Pasinetti GM. Grape-
derived polyphenolics prevent Abeta oligomerization 
and attenuate cognitive deterioration in a mouse model 
of Alzheimer's disease. J Neurosci. 2008; 28(25): 
6388–6392. doi:10.1523/JNEUROSCI.0364-08.2008 
84. Sweatt JD. Mitogen-activated protein kinases in 
synaptic plasticity and memory. Curr Opin Neurobiol. 
2004; 14(3): 311–317.  
doi: 10.1016/j.conb.2004.04.001 
85. Kim T, Hinton DJ, Choi DS. Protein kinase C-regulated 
aβ production and clearance. Int J Alzheimers Dis. 
2011; 2011: 857368. doi:10.4061/2011/857368  
86. Mega MS.  The cholinergic deficit in Alzheimer's 
disease: Impact on cognition, behaviour and function. 
Int J Neuropsychopharmacol. 2000; 3(7): 3–12. doi: 
10.1017/S1461145700001942 
87. Fadda F, Rossetti ZL. Chronic ethanol consumption: 
from neuroadaptation to neurodegeneration. Progress 
Neurobiol. 1998; 56(4): 385–431. doi: 10.1016/s0301-
0082(98)00032-x 
88. Singh NA, Mandal AKA, Khan ZA. Potential 
neuroprotective properties of epigallocatechin-3-
gallate (EGCG). Nutr J. 2015; 15(1): 60. doi: 
10.1186/s12937-016-0179-4 
89. Munoz FJ, Aldunate R, Inestrosa NC. Peripheral 
binding site is involved in the neurotrophic activity of 
acetylcholinesterase. Neuroreport. 1999; 10(17): 
3621–3625. doi: 10.1097/00001756-199911260-00029 
90. Heymann D, Stern Y, Cosentino S, Tatarina-Nulman 
O, Dorrejo JN, Gu Y. The association between alcohol 
use and the progression of Alzheimer’s disease. Curr 
Alzheimer Res. 2016; 13(12): 1356–1362. doi: 
10.2174/1567205013666160603005035 
91. Bate C, Williams A. Ethanol protects cultured neurons 
against amyloid-β and α-synuclein-induced synapse 
damage. Neuropharmacology. 2011; 61(8): 1406–
1412. doi: 10.1016/j.neuropharm.2011.08.030 
92. Habtemariam S. The brain-derived neurotrophic factor 
in neuronal plasticity and neuroregeneration: new 
pharmacological concepts for old and new drugs. 
Neural Regen Res. 2018; 13(6): 983–984. doi: 
10.4103/1673-5374.23343 
93. Logrip ML, Barak S, Warnault V, Ron D. 
Corticostriatal BDNF and alcohol addiction. Brain Res. 
2015; 1628(ptA): 60–67. 
94. van Grootheest G, Milaneschi Y, Lips PTAM, Heijboer 
AC, Smit JH, Penninx BWJH. Determinants of plasma 
25-hydroxyvitamin D levels in healthy adults in the 
Netherlands. Neth J Med. 2014;72(10):533–540. 
95. Gorter EA, Krijnen P, Schipper IB. Vitamin D 
deficiency in adult fracture patients: prevalence and 
risk factors. Eur J Trauma Emerg Surg. 2016;42(3): 
369–378. doi:10.1007/s00068-015-0550-8 
96. Tardelli VS, Lago MPPD, Silveira DXD, Fidalgo TM. 
Vitamin D and alcohol: A review of the current 
literature. Psychiatry Res. 2017; 248: 83–86. doi: 
10.1016/j.psychres.2016.10.051 
97. Siddiquee AT, Kadota A, Fujiyoshi A, Miyagawa N, 
Saito Y, Suzuki H, Kondo K, Yamauchi H, Ito T, 
Segawa H, Tooyama I, Miura K, Ueshima H, SESSA 
Research Group. Alcohol consumption and cognitive 
function in elderly Japanese men. Alcohol. 2020;85: 
145–152. doi: 10.1016/j.alcohol.2020.01.001 
98. Velikova M, Stoyanov Z. Alcohol and the cognitive 
functions of the aging brain. Journal of the Union of 
Scientists - Varna. Medicine and Ecology Series. 2019; 
24(1): 61–65. 
99. Topiwala A, Allan CL, Valkanova V, Zsoldos E, 
Filippini N, Sexton C, Mahmood A, Fooks P, Singh-
Manoux A, Mackay CE, Kivimäki M, Ebmeier KP. 
Moderate alcohol consumption as risk factor for 
adverse brain outcomes and cognitive decline: 
longitudinal cohort study. BMJ. 2017; 357: j2353. doi: 
10.1136/bmj.j2353. 
100. Albu CV, Pădureanu V, Boldeanu MV, Bumbea AM, 
Enescu AŞ, Albulescu DM, Siloși CA, Enescu A. 
Vascular neurocognitive disorders and the vascular risk 
factors. J Mind Med Sci. 2018; 5(1): 7–5. doi: 
10.22543/7674.51.P71 
